Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Qualifying a human Liver-Chip for predictive toxicology: Performance assessment and economic implications

ABSTRACT: Qualifying a human Liver-Chip for predictive toxicology: Performance assessment and economic implications

PROVIDER: PRJNA854895 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR19918616_1.fastq.gz	Fastqsanger.gz
	SRR19918616_2.fastq.gz	Fastqsanger.gz
	SRR19918617_1.fastq.gz	Fastqsanger.gz
	SRR19918617_2.fastq.gz	Fastqsanger.gz
	SRR19918618_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 44

Similar Datasets

Qualifying a human Liver-Chip for predictive toxicology: Performance assesment and economic implications

Project description:Qualifying a human Liver-Chip for predictive toxicology: Performance assesment and economic implications

| PRJNA799303 | ENA

Qualifying a human Liver-Chip for predictive toxicology: Performance assessment and economic implications

Project description:We assess RNA expression in human primary hepatocytes in Vials Day 0 and Liver-Chips on Day 3 and Day 7 for two different donors. The hepatocytes were co-cultured in Liver-Chip model with Kupffer cells and Liver sinusoidal endothelial cells (LSECs) and stellate cells .

2022-10-14 | GSE207339 | GEO

Qualifying a human Liver-Chip for predictive toxicology: Performance assesment and economic implications

Project description:We assess RNA expression in human primary hepatocytes in Liver-Chips on Day 3 and Day 5. The hepatocytes were co-cultured in Liver-Chip model with Kupffer cells, Liver sinusoidal endothelial cells (LSECs) and stellate cells .

2025-01-21 | GSE194147 | GEO

Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology.

Project description:BackgroundConventional preclinical models often miss drug toxicities, meaning the harm these drugs pose to humans is only realized in clinical trials or when they make it to market. This has caused the pharmaceutical industry to waste considerable time and resources developing drugs destined to fail. Organ-on-a-Chip technology has the potential improve success in drug development pipelines, as it can recapitulate organ-level pathophysiology and clinical responses; however, systematic and quantitative evaluations of Organ-Chips' predictive value have not yet been reported.Methods870 Liver-Chips were analyzed to determine their ability to predict drug-induced liver injury caused by small molecules identified as benchmarks by the Innovation and Quality consortium, who has published guidelines defining criteria for qualifying preclinical models. An economic analysis was also performed to measure the value Liver-Chips could offer if they were broadly adopted in supporting toxicity-related decisions as part of preclinical development workflows.ResultsHere, we show that the Liver-Chip met the qualification guidelines across a blinded set of 27 known hepatotoxic and non-toxic drugs with a sensitivity of 87% and a specificity of 100%. We also show that this level of performance could generate over $3 billion annually for the pharmaceutical industry through increased small-molecule R&D productivity.ConclusionsThe results of this study show how incorporating predictive Organ-Chips into drug development workflows could substantially improve drug discovery and development, allowing manufacturers to bring safer, more effective medicines to market in less time and at lower costs.

| S-EPMC9727064 | biostudies-literature

Systems toxicology assessment of CHTP1.2 [RNE Data]

Project description:Modified risk tobacco products (MRTPs) have the potential to reduce smoking-related health risks. The Carbon Heated Tobacco Product 1.2 (CHTP1.2) is a potential MRTP that uses a pressed carbon heat source to generate an aerosol by heating tobacco. This study reports the results from the systems toxicology arm of a 90-day rat inhalation study (OECD test guideline 413) to assess the effects of CHTP1.2 aerosol compared with cigarette smoke (CS). Rats were exposed to filtered air (sham), to CHTP1.2 aerosol (at 15, 23 and 50 µg nicotine / L), or to the 3R4F reference cigarette smoke (at 23 µg nicotine / L).

2018-04-10 | E-MTAB-6320 | biostudies-arrayexpress

Systems toxicology assessment of CHTP1.2 [Liver Data]

2018-04-10 | E-MTAB-6317 | biostudies-arrayexpress

Systems toxicology assessment of CHTP1.2 [Lung Data]

2018-04-10 | E-MTAB-6319 | biostudies-arrayexpress

Systems toxicology assessment of CHTP1.2 [Lung Data]

Project description:Modified risk tobacco products (MRTPs) have the potential to reduce smoking-related health risks. The Carbon Heated Tobacco Product 1.2 (CHTP1.2) is a potential MRTP that uses a pressed carbon heat source to generate an aerosol by heating tobacco. This study reports the results from the systems toxicology arm of a 90-day rat inhalation study (OECD test guideline 413) to assess the effects of CHTP1.2 aerosol compared with cigarette smoke (CS). Rats were exposed to filtered air (sham), to CHTP1.2 aerosol (at 15, 23 and 50 Âµg nicotine / L), or to the 3R4F reference cigarette smoke (at 23 Âµg nicotine / L).

2018-03-19 | PXD008422 | Pride

Systems toxicology assessment of CHTP1.2 [RNE Data]

2018-03-19 | PXD008424 | Pride

Systems toxicology assessment of CHTP1.2 [Liver Data]

2018-03-19 | PXD008423 | Pride